Celebrating 25 years of innovation in anti-infectives
For 25 years, Basilea has been at the forefront of creating anti-infective solutions, shaping the future of infectious disease treatment. Our journey has been defined by achievements and a relentless pursuit of excellence. We have always been committed to developing and commercializing innovative medicines to help patients with serious and life-threatening conditions. As we reflect, we are reminded of how far we've come - and how much further we will go.
Here's to 25 years of achievements, innovation, and partnerships. We are proud of our commercial partnerships with Advanz Pharma, Asahi Kasei Pharma, Astellas Pharma, Avir Pharma, CR Gosun, Hikma Pharmaceuticals, Innoviva Specialty Therapeutics, JSC Lancet, Knight Therapeutics, Pfizer Inc. and Unimedic Pharma. To date, our partners are covering more than 100 countries. Together, we continue to make a difference for patients around the world.
-
2000
October 17th: Basilea is born
-
2004
Going public - IPO on SIX
-
2008
Reaching the market – hand eczema drug Toctino approved in Europe
-
2010
Partner with Astellas Pharma. Inc. for the development and commercialization of antifungal Cresemba (isavuconazole)
-
2012
Exit dermatology, Toctino sold to GlaxoSmithKline
-
2013
Antibiotic Zevtera (ceftobiprole) approved in Europe
-
2015
Cresemba approved in Europe and the USA
-
2016
BARDA agrees to fund phase 3 studies for Zevtera for the US
-
2017
Partner with Pfizer Inc. for the commericialization of Cresemba in Europe/APAC and China
-
2019
Global annual in-market sales of Cresemba reach USD 200 million
-
2019
Positive results for first Zevtera phase 3 study for the US
-
2021
Global annual in-market sales of Cresemba reach USD 300 million
-
2022
Relocation of corporate headquarters to Allschwil
-
2022
Strategic decision to focus exclusively on anti-infectives and to divest oncology assets
-
2022
Positive results for second Zevtera phase 3 study for the US
-
2023
Global annual in-market sales of Cresemba reach USD 400 million
-
2023
Acquisition of rights to the antifungal drug fosmanogepix from Pfizer
-
2024
Approval of Zevtera in the US
-
2024
Agreement with BARDA for funding of development of antifungals and antibacterials
-
2024
Start of first fosmanogepix phase 3 study
-
2024
Agreement with Innoviva Specialty Therapeutics (IST) for the commercialization of Zevtera in the US
-
2024
Global annual in-market sales of Cresemba reach USD 500 million
Entering a new chapter
Basilea is a dynamic Swiss biotech company dedicated to improving patients' lives with innovative anti-infective medicines. Rooted in expertise, care, and persistence, we are evolving our visual identity to reflect our forward-thinking, growth-driven approach to healthcare. Our brand stands for reliability, professionalism, and passion, reinforcing our role as a trusted leader in innovative medicines. With Swiss precision and a focus on human care, we are committed to driving meaningful change in the fight against infectious diseases.
As we embark on this new chapter, we're excited to unveil a bold, refreshed look that embodies our commitment to progress, innovation, and the exciting future ahead. Building on our rich history, we continue to push boundaries, improving how we work and communicate to ensure we remain at the forefront of anti-infective advancements that benefit patients worldwide. The next phase of Basilea is here, and we are more energized than ever to lead the charge in tackling infectious diseases.
Stay tuned as we gradually update our communication platforms - more to come!
